162 related articles for article (PubMed ID: 22644968)
1. Taliglucerase alfa approved for Gaucher disease.
Traynor K
Am J Health Syst Pharm; 2012 Jun; 69(12):1009. PubMed ID: 22644968
[No Abstract] [Full Text] [Related]
2. Long-term efficacy and safety results of taliglucerase alfa through 5years in adult treatment-naïve patients with Gaucher disease.
Zimran A; Durán G; Giraldo P; Rosenbaum H; Giona F; Petakov M; Terreros Muñoz E; Solorio-Meza SE; Cooper PA; Varughese S; Alon S; Chertkoff R
Blood Cells Mol Dis; 2019 Sep; 78():14-21. PubMed ID: 27499018
[TBL] [Abstract][Full Text] [Related]
3. Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase.
Pastores GM; Shankar SP; Petakov M; Giraldo P; Rosenbaum H; Amato DJ; Szer J; Chertkoff R; Brill-Almon E; Zimran A
Am J Hematol; 2016 Jul; 91(7):661-5. PubMed ID: 27102949
[TBL] [Abstract][Full Text] [Related]
4. Taliglucerase alfa: an enzyme replacement therapy using plant cell expression technology.
Grabowski GA; Golembo M; Shaaltiel Y
Mol Genet Metab; 2014 May; 112(1):1-8. PubMed ID: 24630271
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment-naïve patients with Gaucher disease.
Zimran A; Durán G; Mehta A; Giraldo P; Rosenbaum H; Giona F; Amato DJ; Petakov M; Muñoz ET; Solorio-Meza SE; Cooper PA; Varughese S; Chertkoff R; Brill-Almon E
Am J Hematol; 2016 Jul; 91(7):656-60. PubMed ID: 27174694
[TBL] [Abstract][Full Text] [Related]
6. Taliglucerase alfa in Gaucher disease: Description of a Brazilian experience.
Cravo R; Rotman V; Oliveira PMN; Defendi HGT; Conceição DA; Xavier JR; Chertkoff R; Noronha TG; Maia MLS
Blood Cells Mol Dis; 2018 Feb; 68():160-162. PubMed ID: 28131618
[TBL] [Abstract][Full Text] [Related]
7. A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.
Pastores GM; Petakov M; Giraldo P; Rosenbaum H; Szer J; Deegan PB; Amato DJ; Mengel E; Tan ES; Chertkoff R; Brill-Almon E; Zimran A
Blood Cells Mol Dis; 2014 Dec; 53(4):253-60. PubMed ID: 24950666
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in treatment approaches to Gaucher disease.
Elstein D
Curr Pharm Biotechnol; 2011 Jun; 12(6):854-60. PubMed ID: 21235447
[TBL] [Abstract][Full Text] [Related]
9. 13,845 home therapy infusions with velaglucerase alfa exemplify safety of velaglucerase alfa and increased compliance to every-other-week intravenous enzyme replacement therapy for Gaucher disease.
Elstein D; Abrahamov A; Oz A; Arbel N; Baris H; Zimran A
Blood Cells Mol Dis; 2015 Dec; 55(4):415-8. PubMed ID: 26460268
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of Novel Plant Cell-Expressed Taliglucerase Alfa in Adult and Pediatric Patients with Gaucher Disease.
Abbas R; Park G; Damle B; Chertkoff R; Alon S
PLoS One; 2015; 10(6):e0128986. PubMed ID: 26053270
[TBL] [Abstract][Full Text] [Related]
11. Early access experience with VPRIV(®): recommendations for 'core data' collection.
Hughes DA; Al-Sayed M; Belmatoug N; Bodamer O; Böttcher T; Cappellini M; Cohen IJ; Eagleton T; Elstein D; Giraldo P; Jones S; Kaplinsky C; Lund A; Machaczka M; Mengel E; Pastores GM; Rosenbaum H; Sjo M; Tiling N; Tsaftaridis P; Zimran A; Weinreb N
Blood Cells Mol Dis; 2011 Aug; 47(2):140-2. PubMed ID: 21146428
[No Abstract] [Full Text] [Related]
12. Competing for the treasure in exceptions.
Cox TM
Am J Hematol; 2013 Mar; 88(3):163-5. PubMed ID: 23400870
[No Abstract] [Full Text] [Related]
13. Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase.
Zimran A; Gonzalez-Rodriguez DE; Abrahamov A; Cooper PA; Varughese S; Giraldo P; Petakov M; Tan ES; Chertkoff R
Blood Cells Mol Dis; 2018 Feb; 68():163-172. PubMed ID: 27839981
[TBL] [Abstract][Full Text] [Related]
14. Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease.
Zimran A; Wajnrajch M; Hernandez B; Pastores GM
Orphanet J Rare Dis; 2018 Feb; 13(1):36. PubMed ID: 29471850
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease.
Zimran A; Gonzalez-Rodriguez DE; Abrahamov A; Elstein D; Paz A; Brill-Almon E; Chertkoff R
Blood Cells Mol Dis; 2015 Jan; 54(1):9-16. PubMed ID: 25453586
[TBL] [Abstract][Full Text] [Related]
16. Extended remission of B-cell lymphoma with monoclonal gammopathy in a patient with type 1 Gaucher disease treated with enzyme replacement therapy.
Camou F; Viallard JF
Blood Cells Mol Dis; 2012 Jan; 48(1):51-2. PubMed ID: 21983348
[No Abstract] [Full Text] [Related]
17. Home infusion of intravenous velaglucerase alfa: Experience from pooled clinical studies in 104 patients with type 1 Gaucher disease.
Elstein D; Burrow TA; Charrow J; Giraldo P; Mehta A; Pastores GM; Lee HM; Mellgard B; Zimran A
Mol Genet Metab; 2017; 120(1-2):111-115. PubMed ID: 27614581
[TBL] [Abstract][Full Text] [Related]
18. Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease.
van Dussen L; Zimran A; Akkerman EM; Aerts JM; Petakov M; Elstein D; Rosenbaum H; Aviezer D; Brill-Almon E; Chertkoff R; Maas M; Hollak CE
Blood Cells Mol Dis; 2013 Mar; 50(3):206-11. PubMed ID: 23199589
[TBL] [Abstract][Full Text] [Related]
19. Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: early Access Program results from Jerusalem.
Elstein D; Altarescu G; Maayan H; Phillips M; Abrahamov A; Hadas-Halpern I; Tiomkin M; Zimran A
Blood Cells Mol Dis; 2012 Jan; 48(1):45-50. PubMed ID: 22047948
[TBL] [Abstract][Full Text] [Related]
20. Position statement: National Gaucher Foundation Medical Advisory Board, January 7, 2014.
Barranger JA; Brady RO; Grabowski GA; Mankin H; Mistry PK; Weinreb NJ
Am J Hematol; 2014 May; 89(5):457-8. PubMed ID: 24488939
[No Abstract] [Full Text] [Related]
[Next] [New Search]
